Patents by Inventor Yeong-Wook Song
Yeong-Wook Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11987645Abstract: A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.Type: GrantFiled: July 2, 2019Date of Patent: May 21, 2024Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Yeong Wook Song, Joo Youn Lee, Eugene C. Yi, Min Jueng Kang
-
Publication number: 20230110385Abstract: A system and method for the detection of autoantibodies in saliva is described. In particular, the system is suitable for detecting an autoantibody in a subject, wherein the presence of the autoantibody is indicative of the presence or increased risk of development of an autoimmune disease or disorder.Type: ApplicationFiled: March 3, 2021Publication date: April 13, 2023Inventors: Fang Wei, Sarah Kamounah, Anne Marie Lynge Pedersen, Yeong Wook Song, David Chia, David T. Wong
-
Publication number: 20220211754Abstract: The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1?, TNF-?, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.Type: ApplicationFiled: April 29, 2020Publication date: July 7, 2022Inventors: Kyuboem HAN, Chun-Hyung KIM, Shin-Hye YU, Seo-Eun LEE, Sang-Min LIM, Hahnsun JUNG, Kwangmin NA, Yoon Mi HAN, Jun Young SON, Eun Young LEE, Jeong Yeon KIM, Yeong Wook SONG, Jin Chul PAENG, Yun Sang LEE, Do Won HWANG
-
Publication number: 20210221847Abstract: A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.Type: ApplicationFiled: July 2, 2019Publication date: July 22, 2021Inventors: Yeong Wook SONG, Joo Youn LEE, Eugene C. YI, Min Jueng KANG
-
Patent number: 10087248Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.Type: GrantFiled: May 22, 2014Date of Patent: October 2, 2018Assignee: METABOLIC ENGINEERING LABORATORIES CO., LTD.Inventors: Heun-Soo Kang, So-Hyun Park, Yeong Wook Song, Ki Chul Shin, Eun Young Lee, Eun Bong Lee, Young Woo Park, Bum-Chan Park, Dong Hee Lee, Dong Jin Kim, Seon Ha Yun, Ke Se Lee, Hyun Ju Lee, Kyung Jin Kim, Hee Chan Kim, Seok Ho Yoo, Myeoung Hee Jang, Seil Jang
-
Patent number: 9725507Abstract: The present invention relates to a novel epitope of IP-10 (IFN-?-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to IP-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to IP-10. The anti-IP-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to IP-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.Type: GrantFiled: September 17, 2013Date of Patent: August 8, 2017Assignee: SNU R&DB FOUNDATIONInventor: Yeong Wook Song
-
Publication number: 20160108118Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.Type: ApplicationFiled: May 22, 2014Publication date: April 21, 2016Applicant: METABOLIC ENGINEERING LABORATORIES CO., LTD.Inventors: Heun-Soo Kang, So-Hyun Park, Yeong Wook Song, Ki Chul Shin, Eun Young Lee, Eun Bong Lee, Young Woo Park, Bum-Chan Park, Dong Hee Lee, Dong Jin Kim, Seon Ha Yun, Ke Se Lee, Hyun Ju Lee, Kyung Jin Kim, Hee Chan Kim, Seok Ho Yoo, Myeoung Hee Jang, Seil Jang
-
Publication number: 20150266951Abstract: The present invention relates to a novel epitope of IP-10 (IFN-?-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to IP-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to IP-10. The anti-IP-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to IP-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.Type: ApplicationFiled: September 17, 2013Publication date: September 24, 2015Applicant: SNU R&DB FOUNDATIONInventor: Yeong Wook Song
-
Publication number: 20120178633Abstract: The present invention relates to a diagnostic composition for autoimmune diseases, comprising agent measuring a methylation level of CD3Z gene, a diagnostic method and a kit using the same. More particularly, the present invention relates to a composition for diagnosing autoimmune diseases according to the methylation level of CD3Z gene, or additionally ADA or VHL gene, and a method for diagnosing autoimmune diseases by measuring the methylation level. The methylation of any one or more of the ADA, VHL, and CD3Z genes of the present invention is specific to autoimmune diseases, and thus the composition comprising an agent measuring a methylation level of the present invention can be used for the diagnosis of autoimmune diseases.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicants: SNU R&DB FOUNDATION, NATIONAL CANCER CENTERInventors: Kyeong Man HONG, Yeong Wook SONG
-
Patent number: 7476540Abstract: The present invention relates to monoclonal antibodies specifically binding to a membrane antigen of human mesenchymal stem cells, hybridoma cell lines producing the same, and methods for identifying or isolating human mesenchymal stem cells using the same. The monoclonal antibodies of this invention exhibit excellent specificity to human mesenchymal stem cells, inter alia, bone marrow-derived human mesenchymal stem cells, so that it allows for the identification and isolation of human mesenchymal stem cells with much higher specificity.Type: GrantFiled: January 10, 2006Date of Patent: January 13, 2009Assignee: Seoul National University Industry FoundationInventors: Yeong-Wook Song, Hyun-Jung Yoo, Sung-Soo Yoon, Seonyang Park, Weon-Seo Park, Dong-Jo Kim, Eun-Bong Lee
-
Publication number: 20070161050Abstract: The present invention relates to monoclonal antibodies specifically binding to a membrane antigen of human mesenchymal stem cells, hybridoma cell lines producing the same, and methods for identifying or isolating human mesenchymal stem cells using the same. The monoclonal antibodies of this invention exhibit excellent specificity to human mesenchymal stem cells, inter alia, bone marrow-derived human mesenchymal stem cells, so that it allows for the identification and isolation of human mesenchymal stem cells with much higher specificity.Type: ApplicationFiled: January 10, 2006Publication date: July 12, 2007Applicant: Seoul National University Industry FoundationInventors: Yeong-Wook Song, Hyun-Jung Yoo, Sung-Soo Yoon, Seonyang Park, Weon-Seo Park, Dong-Jo Kim, Eun-Bong Lee